Cleveland, OH, October 07, 2019. Haima Therapeutics (Haima), a pre-clinical biotechnology company focused on developing bio-inspired therapies to mitigate bleeding, announced today the formation of its Scientific Advisory Board (SAB) comprised of four, world-renowned scientists and clinicians in the field of engineering, trauma, surgery, hemostasis, and critical care. They will provide external scientific review and high-level advice to Haima’s management with regards to its preclinical R&D activities and clinical development strategy for its lead candidate SynthoPlate, a platelet-inspired fully-synthetic nanoparticle-based hemostatic technology.
Cleveland, OH, June 1, 2019. Haima Therapeutics has been awarded a $300K Phase I Small Business Innovation Research (SBIR) grant from the National Heart, Lung, And Blood Institute of the National Institutes of Health (NIH) to support the development of SynthoPlateTM, an hemostatic nanotechnology to mitigate bleeding in thrombocytopenic patients.
May 15, 2019, Austin, TX. Haima Therapeutics was Selected for MassChallenge Texas in Austin 2019 Accelerator
Haima joins MassChallenge’s global network of startups
May 2, 2019. For centuries scientists have sought an artificial substitute for blood. Equipped with modern nanotechnology and a humbler strategy, bioengineers think they’re closer than ever. Read more.
October 1, 2018. COLUMBUS – Secretary of State Jon Husted has announced October as “Ohio’s Future” Month. Throughout the month, Ohio Business Profile will highlight a series of businesses who are using innovation to drive the future of the Buckeye State. Haima Therapeutics LLC was chosen to be highlighted.
September 5, 2018. Haima Therapeutics has been awarded a $150K Phase I SBIR contract from the US Army Research, Development, and Engineering Command (RDECOM) for research titled “Logistical and Functional Evaluation of SynthoPlateTM (Intravenous Synthetic Platelet) Technology for Pre-Hospital Hemorrhage Control”.
June 7, 2018. CWRU and Haima Therapeutics have agreed that Haima can license SynthoPlate, an artificial platelet product. The Plain Dealer, the prime Cleveland news source, interviewed the inventor/Co-Founder, Dr. Anirban Sen Gupta, and Co-Founder and CSO, Dr. Christa Pawlowski.
June 7, 2018. Case Western Reserve University and Cleveland-based biotechnology company Haima Therapeutics have signed a two-year option to license a technology to prevent and treat bleeding complications from trauma, low platelet counts, and surgery, according to a news release.
January 1, 2018. Haima Therapeutics has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $225,000 from the National Science Foundation to pursue manufacturing and characterization of the SynthoPlate technology.
September, 11, 2017. Dr. Sen Gupta's group at CWRU, in collaboration with Drs. Matthew Neal and Ronald Poropatich at University of Pittsburgh Medical Center and Drs. Rodney Chan and Anders Carlsson at US Army Institute of Surgical Research, has received a Prolonged Field Care Research Award from the Department of Defense.